JP2023011793A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023011793A5 JP2023011793A5 JP2022175211A JP2022175211A JP2023011793A5 JP 2023011793 A5 JP2023011793 A5 JP 2023011793A5 JP 2022175211 A JP2022175211 A JP 2022175211A JP 2022175211 A JP2022175211 A JP 2022175211A JP 2023011793 A5 JP2023011793 A5 JP 2023011793A5
- Authority
- JP
- Japan
- Prior art keywords
- chimeric antisense
- antisense oligonucleotide
- nucleosides
- sequence
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108091034117 Oligonucleotide Proteins 0.000 claims 27
- 239000000074 antisense oligonucleotide Substances 0.000 claims 27
- 238000012230 antisense oligonucleotides Methods 0.000 claims 27
- 125000003835 nucleoside group Chemical group 0.000 claims 16
- 239000002777 nucleoside Substances 0.000 claims 15
- 239000008194 pharmaceutical composition Substances 0.000 claims 12
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 claims 8
- 239000003446 ligand Substances 0.000 claims 6
- 230000008685 targeting Effects 0.000 claims 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 4
- OVRNDRQMDRJTHS-KEWYIRBNSA-N N-acetyl-D-galactosamine Chemical group CC(=O)N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-KEWYIRBNSA-N 0.000 claims 4
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 claims 4
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims 4
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 claims 4
- 108020000948 Antisense Oligonucleotides Proteins 0.000 claims 3
- 150000003833 nucleoside derivatives Chemical class 0.000 claims 3
- 150000004713 phosphodiesters Chemical class 0.000 claims 3
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 claims 2
- MSSXOMSJDRHRMC-UHFFFAOYSA-N 9H-purine-2,6-diamine Chemical compound NC1=NC(N)=C2NC=NC2=N1 MSSXOMSJDRHRMC-UHFFFAOYSA-N 0.000 claims 2
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 claims 2
- 229930024421 Adenine Natural products 0.000 claims 2
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 claims 2
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 claims 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 229960000643 adenine Drugs 0.000 claims 2
- 230000000295 complement effect Effects 0.000 claims 2
- 229940104302 cytosine Drugs 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 150000007523 nucleic acids Chemical group 0.000 claims 2
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims 2
- 229940113082 thymine Drugs 0.000 claims 2
- 229940035893 uracil Drugs 0.000 claims 2
- 108700005077 Viral Genes Proteins 0.000 claims 1
- 108020000999 Viral RNA Proteins 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 230000008018 melting Effects 0.000 claims 1
- 238000002844 melting Methods 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000004962 physiological condition Effects 0.000 claims 1
- 230000010076 replication Effects 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662394738P | 2016-09-14 | 2016-09-14 | |
| US201662394739P | 2016-09-14 | 2016-09-14 | |
| US62/394,738 | 2016-09-14 | ||
| US62/394,739 | 2016-09-14 | ||
| JP2019514088A JP6970187B2 (ja) | 2016-09-14 | 2017-09-14 | 修飾オリゴヌクレオチド及び使用方法 |
| JP2021176346A JP7170820B2 (ja) | 2016-09-14 | 2021-10-28 | 修飾オリゴヌクレオチド及び使用方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021176346A Division JP7170820B2 (ja) | 2016-09-14 | 2021-10-28 | 修飾オリゴヌクレオチド及び使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023011793A JP2023011793A (ja) | 2023-01-24 |
| JP2023011793A5 true JP2023011793A5 (https=) | 2023-04-17 |
| JP7478210B2 JP7478210B2 (ja) | 2024-05-02 |
Family
ID=59955744
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019514088A Expired - Fee Related JP6970187B2 (ja) | 2016-09-14 | 2017-09-14 | 修飾オリゴヌクレオチド及び使用方法 |
| JP2021176346A Active JP7170820B2 (ja) | 2016-09-14 | 2021-10-28 | 修飾オリゴヌクレオチド及び使用方法 |
| JP2022175211A Active JP7478210B2 (ja) | 2016-09-14 | 2022-11-01 | 修飾オリゴヌクレオチド及び使用方法 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019514088A Expired - Fee Related JP6970187B2 (ja) | 2016-09-14 | 2017-09-14 | 修飾オリゴヌクレオチド及び使用方法 |
| JP2021176346A Active JP7170820B2 (ja) | 2016-09-14 | 2021-10-28 | 修飾オリゴヌクレオチド及び使用方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US10793859B2 (https=) |
| EP (1) | EP3512949A1 (https=) |
| JP (3) | JP6970187B2 (https=) |
| KR (3) | KR20240010761A (https=) |
| CN (1) | CN109952378B (https=) |
| AU (2) | AU2017326372B2 (https=) |
| BR (1) | BR112019004911A2 (https=) |
| CA (1) | CA3037042A1 (https=) |
| IL (2) | IL265359B2 (https=) |
| MA (1) | MA46422A (https=) |
| MX (2) | MX2019002960A (https=) |
| TW (1) | TWI769177B (https=) |
| WO (1) | WO2018053185A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2017326372B2 (en) | 2016-09-14 | 2023-12-07 | Janssen Biopharma, Inc. | Modified oligonucleotides and methods of use |
| EP3682007A2 (en) * | 2017-09-14 | 2020-07-22 | Janssen BioPharma, Inc. | Galnac derivatives |
| IL273274B2 (en) * | 2017-09-14 | 2023-12-01 | Janssen Biopharma Llc | Modified nucleoside phosphoramidites |
| PE20211783A1 (es) * | 2018-11-08 | 2021-09-08 | Aligos Therapeutics Inc | Polimeros oligonucleotidos que inhiben el transporte de antigenos y metodos |
| WO2021198958A1 (en) * | 2020-04-01 | 2021-10-07 | Janssen Biopharma, Inc. | Nucleic acid polymers |
| CA3187388A1 (en) * | 2020-07-27 | 2022-02-03 | Jin Hong | Hbv binding oligonucleotides and methods of use |
| CN114057816B (zh) * | 2020-07-30 | 2025-02-11 | 浙江柏拉阿图医药科技有限公司 | 富含腺嘌呤硫代磷酸酯化寡核苷酸及其抗肝炎病毒的应用 |
| WO2022153358A1 (ja) | 2021-01-12 | 2022-07-21 | 日本電気株式会社 | 秘密計算システム、秘密計算サーバ装置、秘密計算方法および秘密計算プログラム |
| WO2023131926A2 (en) | 2022-01-10 | 2023-07-13 | Ausper Biopharma Co., Ltd. | Modulation of hepatitis b virus (hbv) expression |
| TW202508607A (zh) * | 2023-05-19 | 2025-03-01 | 大陸商北京炫景瑞醫藥科技有限公司 | 雙股寡核苷酸及其共軛物和用途 |
| US20250345389A1 (en) * | 2024-05-13 | 2025-11-13 | Gilead Sciences, Inc. | Combination therapies |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002081494A1 (en) | 2001-03-26 | 2002-10-17 | Sirna Therapeutics, Inc. | Oligonucleotide mediated inhibition of hepatitis b virus and hepatitis c virus replication |
| HUT76094A (en) | 1994-03-18 | 1997-06-30 | Lynx Therapeutics | Oligonucleotide n3'-p5' phosphoramidates: synthesis and compounds; hybridization and nuclease resistance properties |
| US6770748B2 (en) | 1997-03-07 | 2004-08-03 | Takeshi Imanishi | Bicyclonucleoside and oligonucleotide analogue |
| JP3756313B2 (ja) | 1997-03-07 | 2006-03-15 | 武 今西 | 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体 |
| US6794499B2 (en) | 1997-09-12 | 2004-09-21 | Exiqon A/S | Oligonucleotide analogues |
| CZ296576B6 (cs) | 1999-02-12 | 2006-04-12 | Sankyo Company Limited | Nukleosidový analog a oligonukleotidový analog a farmaceutický prostredek, sonda a primer s jeho obsahem |
| US7084125B2 (en) | 1999-03-18 | 2006-08-01 | Exiqon A/S | Xylo-LNA analogues |
| EP1178999B1 (en) | 1999-05-04 | 2007-03-14 | Santaris Pharma A/S | L-ribo-lna analogues |
| US6525191B1 (en) | 1999-05-11 | 2003-02-25 | Kanda S. Ramasamy | Conformationally constrained L-nucleosides |
| JP4151751B2 (ja) | 1999-07-22 | 2008-09-17 | 第一三共株式会社 | 新規ビシクロヌクレオシド類縁体 |
| CN1317291C (zh) * | 1999-09-10 | 2007-05-23 | 杰龙公司 | 寡核苷酸n3′→p5′硫代氨基磷酸酯,其合成及应用 |
| US7321029B2 (en) | 2000-01-21 | 2008-01-22 | Geron Corporation | 2′-arabino-fluorooligonucleotide N3′→P5′ phosphoramidates: their synthesis and use |
| US7563618B2 (en) * | 2001-03-23 | 2009-07-21 | Geron Corporation | Oligonucleotide conjugates |
| US7569575B2 (en) | 2002-05-08 | 2009-08-04 | Santaris Pharma A/S | Synthesis of locked nucleic acid derivatives |
| US7956176B2 (en) * | 2002-09-05 | 2011-06-07 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
| CA2504694C (en) | 2002-11-05 | 2013-10-01 | Isis Pharmaceuticals, Inc. | Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation |
| WO2005003314A2 (en) * | 2003-06-27 | 2005-01-13 | Isis Pharmaceuticals, Inc. | A method of selecting an active oligonucleotide predictive model |
| ATE503014T1 (de) * | 2003-11-04 | 2011-04-15 | Geron Corp | Rna-amidate und thioamidateur rnai |
| KR20080036650A (ko) * | 2005-08-17 | 2008-04-28 | 시르나 쎄러퓨틱스 인코퍼레이티드 | Ｒｎａ 간섭을 매개하는 화학적으로 변형된 짧은 간섭 핵산분자 |
| US8198253B2 (en) * | 2006-07-19 | 2012-06-12 | Isis Pharmaceuticals, Inc. | Compositions and their uses directed to HBXIP |
| KR20120095397A (ko) * | 2009-10-16 | 2012-08-28 | 글락소 그룹 리미티드 | Ｈｂｖ 안티센스 억제제 |
| WO2011060557A1 (en) | 2009-11-20 | 2011-05-26 | Governors Of The University Of Alberta | Method for selection of aptamers |
| WO2011139911A2 (en) * | 2010-04-29 | 2011-11-10 | Isis Pharmaceuticals, Inc. | Lipid formulated single stranded rna |
| PH12019502377A1 (en) * | 2011-04-21 | 2022-11-14 | Isis Pharmaceuticals Inc | Modulation of hepatitis b virus (hbv) expression |
| HRP20181564T1 (hr) * | 2011-06-30 | 2018-11-30 | Arrowhead Pharmaceuticals, Inc. | Pripravci i postupci za inhibiciju ekspresije gena virusa hepatitisa b |
| WO2013159109A1 (en) | 2012-04-20 | 2013-10-24 | Isis Pharmaceuticals, Inc. | Modulation of hepatitis b virus (hbv) expression |
| EP2885312B1 (en) * | 2012-08-15 | 2025-09-03 | Ionis Pharmaceuticals, Inc. | Method of preparing oligomeric compounds using modified capping protocols |
| US9228189B2 (en) * | 2012-10-26 | 2016-01-05 | Geron Corporation | C-myc antisense oligonucleotides and methods for using the same to treat cell-proliferative disorders |
| TWI710633B (zh) * | 2014-11-10 | 2020-11-21 | 美商阿尼拉製藥公司 | Ｂ型肝炎病毒（ＨＢＶ）ｉＲＮＡ組成物及其用途方法 |
| US10059940B2 (en) * | 2015-01-27 | 2018-08-28 | Minghong Zhong | Chemically ligated RNAs for CRISPR/Cas9-lgRNA complexes as antiviral therapeutic agents |
| AU2017326372B2 (en) | 2016-09-14 | 2023-12-07 | Janssen Biopharma, Inc. | Modified oligonucleotides and methods of use |
-
2017
- 2017-09-14 AU AU2017326372A patent/AU2017326372B2/en not_active Ceased
- 2017-09-14 MA MA046422A patent/MA46422A/fr unknown
- 2017-09-14 BR BR112019004911A patent/BR112019004911A2/pt not_active Application Discontinuation
- 2017-09-14 IL IL265359A patent/IL265359B2/en unknown
- 2017-09-14 TW TW106131624A patent/TWI769177B/zh active
- 2017-09-14 MX MX2019002960A patent/MX2019002960A/es unknown
- 2017-09-14 JP JP2019514088A patent/JP6970187B2/ja not_active Expired - Fee Related
- 2017-09-14 IL IL315071A patent/IL315071A/en unknown
- 2017-09-14 KR KR1020247001776A patent/KR20240010761A/ko not_active Abandoned
- 2017-09-14 KR KR1020197010486A patent/KR102533038B1/ko active Active
- 2017-09-14 KR KR1020237006131A patent/KR102627418B1/ko active Active
- 2017-09-14 WO PCT/US2017/051644 patent/WO2018053185A1/en not_active Ceased
- 2017-09-14 CN CN201780070383.1A patent/CN109952378B/zh active Active
- 2017-09-14 US US15/705,137 patent/US10793859B2/en active Active
- 2017-09-14 CA CA3037042A patent/CA3037042A1/en active Pending
- 2017-09-14 EP EP17772270.9A patent/EP3512949A1/en active Pending
-
2019
- 2019-03-13 MX MX2023014145A patent/MX2023014145A/es unknown
-
2020
- 2020-10-05 US US17/063,080 patent/US12077757B2/en active Active
-
2021
- 2021-10-28 JP JP2021176346A patent/JP7170820B2/ja active Active
-
2022
- 2022-11-01 JP JP2022175211A patent/JP7478210B2/ja active Active
-
2024
- 2024-03-06 AU AU2024201485A patent/AU2024201485A1/en not_active Abandoned
- 2024-08-06 US US18/795,672 patent/US20250092400A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023011793A5 (https=) | ||
| IL315071A (en) | Modified oligonucleotides and pharmaceutical compositions | |
| US5596091A (en) | Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides | |
| JP5677716B2 (ja) | オリゴヌクレオチド類似体を含むキット及び方法並びにオリゴヌクレオチド類似体の使用 | |
| US7572582B2 (en) | Oligonucleotide analogues | |
| AU662298B2 (en) | Modified internucleoside linkages | |
| WO1998000564A1 (en) | Methods and compositions for sequence-specific hybridization of rna by 2'-5' oligonucleotides | |
| JPH08508491A (ja) | ホスホジエステル結合をアミド結合に置き換えたオリゴヌクレオチド | |
| EP0707481B1 (en) | L-2',3'-dideoxy nucleoside analogs as anti-hepatitis b (hbv) and anti-hiv agents | |
| AU2024205223A1 (en) | GalNAc derivatives | |
| JPWO2021178885A5 (https=) | ||
| JP2021072862A5 (https=) | ||
| JPH05505101A (ja) | オリゴヌクレオチド療法における三重らせん形成 | |
| US20030134808A1 (en) | Oligonucleotide analogues | |
| JPH072889A (ja) | ２’−エーテル基を有するヌクレオシド及びオリゴヌクレオチド | |
| JP6542662B2 (ja) | オリゴヌクレオチドアナログのボロン酸結合体 | |
| JPWO2019157531A5 (https=) | ||
| JP2019534862A (ja) | ホスホルアミダイト化学を使用する骨格修飾モルホリノオリゴヌクレオチド及びキメラの合成 | |
| JP2019529406A5 (https=) | ||
| JP2021090458A5 (https=) | ||
| JP2873313B2 (ja) | 化合物 | |
| EP0531436A4 (en) | Sequence-specific nonphotoactivated crosslinking agents which bind to the major groove of duplex dna | |
| JP2021515784A5 (https=) | ||
| CN121194983A (zh) | 5'-膦酸酯修饰的核苷类似物及其制备的寡核苷酸 | |
| WO2021000380A1 (zh) | 修饰核苷、核苷酸和修饰核酸聚合物及其制备方法和应用 |